The microbiome is associated with an increasing number of unmet medical needs

From cancer to obesity, there is growing body of research demonstrating the association between the tens of trillions of bacteria inhabiting our body and a number of severe diseases.

Neurodegenerative diseases, Inflammatory bowel disease, Cardiovascular Diseases, Depression and anxiety, Autoimmune diseases, Asthma and allergies, Dental cavities, Gastric ulcers, Malnutrition, Infections, Diabetes, Eczema, Obesity, Autism, Cancer, Acne…

To address these needs,
Eligo is developing a new class of biotherapeutic agents to
selectively intervene on the microbiome.

We are using proprietary methods in synthetic biology, CRISPR-Cas, and protein engineering to diagnose, eradicate, or functionalize targeted microbial populations.

We are developing a pipeline of therapeutics for unmet medical needs.

We have assembled a strong team of scientists and executives to translate our research into real-world products spanning human and animal health, cosmetics, industrial biotech, food and beverages…

 “Eligo’s technology could be as important as the discovery of penicillin.”  

– Professor Christian Brechot,
Executive director at Institut Pasteur

Career opportunities

Join Our Team